MA40281B1 - Composés de pyrazole et leur utilisation en tant qu' agents de blocage des canaux calciques de type t - Google Patents
Composés de pyrazole et leur utilisation en tant qu' agents de blocage des canaux calciques de type tInfo
- Publication number
- MA40281B1 MA40281B1 MA40281A MA40281A MA40281B1 MA 40281 B1 MA40281 B1 MA 40281B1 MA 40281 A MA40281 A MA 40281A MA 40281 A MA40281 A MA 40281A MA 40281 B1 MA40281 B1 MA 40281B1
- Authority
- MA
- Morocco
- Prior art keywords
- type
- calcium channel
- blocking agents
- channel blocking
- pyrazole compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
- C07D231/40—Acylated on said nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Reproductive Health (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Anesthesiology (AREA)
- Gynecology & Obstetrics (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
L'invention concerne des composés de formule (i) formule (i) dans laquelle x, y, r1, r2, (r4)n, et (r5)m sont tels que définis dans la description, et des sels pharmaceutiquement acceptables de ces composés. Ces composés sont utiles en tant que bloqueurs des canaux calciques de type t
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IB2014061901 | 2014-06-03 | ||
PCT/IB2015/054164 WO2015186056A1 (fr) | 2014-06-03 | 2015-06-02 | Composés de pyrazole et leur utilisation en tant que bloqueurs des canaux calciques de type t |
EP15728640.2A EP3152199B1 (fr) | 2014-06-03 | 2015-06-02 | Composés de pyrazole et leur utilisation en tant qu' agents de blocage des canaux calciques de type t |
Publications (2)
Publication Number | Publication Date |
---|---|
MA40281A MA40281A (fr) | 2015-12-10 |
MA40281B1 true MA40281B1 (fr) | 2018-11-30 |
Family
ID=53385705
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA40281A MA40281B1 (fr) | 2014-06-03 | 2015-06-02 | Composés de pyrazole et leur utilisation en tant qu' agents de blocage des canaux calciques de type t |
Country Status (33)
Country | Link |
---|---|
US (2) | US9932314B2 (fr) |
EP (1) | EP3152199B1 (fr) |
JP (1) | JP6195684B2 (fr) |
KR (1) | KR101906031B1 (fr) |
CN (1) | CN106414429B (fr) |
AR (1) | AR100712A1 (fr) |
AU (1) | AU2015270118C1 (fr) |
CA (1) | CA2947002C (fr) |
CL (1) | CL2016003092A1 (fr) |
CY (1) | CY1120864T1 (fr) |
DK (1) | DK3152199T3 (fr) |
EA (1) | EA031104B1 (fr) |
ES (1) | ES2696351T3 (fr) |
HR (1) | HRP20181670T1 (fr) |
HU (1) | HUE040489T2 (fr) |
IL (1) | IL249275B (fr) |
LT (1) | LT3152199T (fr) |
MA (1) | MA40281B1 (fr) |
MX (1) | MX2016015923A (fr) |
NZ (1) | NZ727818A (fr) |
PE (1) | PE20170129A1 (fr) |
PH (1) | PH12016502230A1 (fr) |
PL (1) | PL3152199T3 (fr) |
PT (1) | PT3152199T (fr) |
RS (1) | RS57943B1 (fr) |
SG (1) | SG11201609974PA (fr) |
SI (1) | SI3152199T1 (fr) |
TN (1) | TN2016000542A1 (fr) |
TR (1) | TR201816624T4 (fr) |
TW (2) | TWI690513B (fr) |
UA (1) | UA121548C2 (fr) |
WO (1) | WO2015186056A1 (fr) |
ZA (1) | ZA201608821B (fr) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HUE040489T2 (hu) | 2014-06-03 | 2019-03-28 | Idorsia Pharmaceuticals Ltd | Pirazolvegyületek és alkalmazásuk t-típusú kalciumcsatorna-blokkolókként |
US10246426B2 (en) | 2014-09-15 | 2019-04-02 | Idorsia Pharmaceuticals Ltd | Triazole compounds as T-type calcium channel blockers |
WO2017139414A1 (fr) * | 2016-02-09 | 2017-08-17 | Inventisbio Inc. | Inhibiteur de l'indoléamine-2,3-dioxygénase (ido) |
US11046683B2 (en) | 2016-12-15 | 2021-06-29 | Ono Pharmaceutical Co., Ltd. | Activator of TREK (TWIK RElated K+ channels) channels |
BR112019011208A2 (pt) * | 2016-12-16 | 2019-10-15 | Idorsia Pharmaceuticals Ltd | combinação farmacêutica, composição farmacêutica, e, kit de partes. |
US20210128537A1 (en) * | 2016-12-21 | 2021-05-06 | Praxis Precision Medicines, Inc. | T-type calcium channel modulators and methods of use thereof |
CN110234622B (zh) * | 2017-02-06 | 2023-07-04 | 爱杜西亚药品有限公司 | 用于合成1-芳基-1-三氟甲基环丙烷的新颖方法 |
WO2019008034A1 (fr) * | 2017-07-05 | 2019-01-10 | Idorsia Pharmaceuticals Ltd | Forme cristalline de n-[1-(5-cyano-pyridin-2-ylméthyl)-1h-pyrazol-3-yl]-2-[4-(1-trifluorométhyl-cyclopropyl)-phényl]-acétamide |
WO2019113693A1 (fr) * | 2017-12-12 | 2019-06-20 | Queen's University At Kingston | Composés et procédés d'inhibition d'enzymes cyp26 |
AU2020311404A1 (en) | 2019-07-11 | 2022-03-03 | Cura Therapeutics, Llc | Sulfone compounds and pharmaceutical compositions thereof, and their therapeutic applications for the treatment of neurodegenerative diseases |
TW202116314A (zh) | 2019-07-11 | 2021-05-01 | 美商普雷西斯精密藥品公司 | T型鈣離子通道調節劑之調配物及其使用方法 |
KR20220119647A (ko) * | 2019-12-20 | 2022-08-30 | 아이도시아 파마수티컬즈 리미티드 | N-[1-(5-시아노-피리딘-2-일메틸)-1h-피라졸-3-일]-2-[4-(1-트리플루오로메틸-시클로프로필)-페닐]-아세트아미드를 포함하는 제약 조성물 |
BR112023026062A2 (pt) * | 2021-07-02 | 2024-03-05 | Lg Chemical Ltd | Método para preparar um composto |
WO2023240205A1 (fr) | 2022-06-10 | 2023-12-14 | Neurocrine Biosciences, Inc. | Composés deutérés |
Family Cites Families (61)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2193725A1 (fr) | 1994-06-24 | 1996-01-04 | David Cavalla | Composes derives d'aryles et utilisation de ces composes comme inhibiteurs de l'activite de la phosphodiesterase iv |
ATE443698T1 (de) | 1996-12-23 | 2009-10-15 | Bristol Myers Squibb Pharma Co | Stickstoffhaltige heterocyclen als faktor xa- hemmer |
WO2002000651A2 (fr) | 2000-06-27 | 2002-01-03 | Bristol-Myers Squibb Pharma Company | Inhibiteurs du facteur xa |
EP1359911A2 (fr) | 2000-12-29 | 2003-11-12 | Alteon, Inc. | Procede de traitement de troubles fibrogenes et autres symptomes de type ivc |
WO2002053160A1 (fr) | 2000-12-29 | 2002-07-11 | Alteon, Inc. | Methode de traitement du glaucome ivb |
ATE455104T1 (de) | 2001-11-01 | 2010-01-15 | Icagen Inc | Pyrazolamide zur anwendung in der behandlung von schmerz |
ATE374194T1 (de) | 2001-12-18 | 2007-10-15 | Merck & Co Inc | Heteroarylsubstituierte triazolmodulatoren des metabotropen glutamatarezeptors 5 |
JP4286146B2 (ja) | 2001-12-18 | 2009-06-24 | メルク エンド カムパニー インコーポレーテッド | メタボトロピックグルタミン酸受容体−5のヘテロアリール置換ピラゾール系調節剤 |
SE0201658D0 (sv) | 2002-05-31 | 2002-05-31 | Astrazeneca Ab | Immediate release pharmaceutical formulation |
AU2004228057A1 (en) | 2003-04-03 | 2004-10-21 | Merck & Co., Inc. | Di-aryl substituted pyrazole modulators of metabotropic glutamate receptor-5 |
EP1613617A4 (fr) | 2003-04-04 | 2009-02-18 | Merck & Co Inc | Modulateurs au triazole a substitution diaryle du recepteur-5 de glutamate metabotropique |
MXPA05011775A (es) * | 2003-05-01 | 2006-02-17 | Abbott Lab | Sulfonamidas y pirazolamidas como moduladores de canal de sodio. |
US20040220170A1 (en) | 2003-05-01 | 2004-11-04 | Atkinson Robert N. | Pyrazole-amides and sulfonamides as sodium channel modulators |
GB0328796D0 (en) | 2003-12-12 | 2004-01-14 | Biofocus Plc | Compounds which interact with the G-protein coupled receptor family |
EP1781662B1 (fr) | 2004-08-18 | 2011-04-20 | Pfizer, Inc. | Inhibiteurs de polymerase d'arn dependant d'arn du virus de l'hepatite c et compositions et traitement utilisant ces inhibiteurs |
WO2006066968A1 (fr) | 2004-12-23 | 2006-06-29 | Glaxo Group Limited | Composes de pyridine destines au traitement de maladies a mediation par prostaglandine |
GB0508472D0 (en) | 2005-04-26 | 2005-06-01 | Glaxo Group Ltd | Compounds |
GB0508463D0 (en) | 2005-04-26 | 2005-06-01 | Glaxo Group Ltd | Compounds |
FR2889234B1 (fr) * | 2005-07-27 | 2007-11-23 | Andre Prieur | Arret de porte a positions de maintien indeterminees |
KR100654328B1 (ko) * | 2005-08-26 | 2006-12-08 | 한국과학기술연구원 | 피페라지닐알킬피라졸계 t-타입 칼슘 채널 억제 화합물 및이의 제조방법 |
US20070197523A1 (en) | 2005-12-22 | 2007-08-23 | Icagen, Inc. | Calcium channel antagonists |
BRPI0710487A2 (pt) * | 2006-04-12 | 2012-06-05 | Merck & Co Inc | composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, uso de um composto ou um sal farmaceuticamente aceitácel do mesmo e, método para tratar ou controlar a epilepsia e a dor e para o tratamento ou prevenção de um distúrbio do sono em um paciente. |
CA2657566A1 (fr) * | 2006-07-24 | 2008-01-31 | F. Hoffmann-La Roche Ag | Pyrazoles comme activateurs de glucokinase |
US7902248B2 (en) | 2006-12-14 | 2011-03-08 | Hoffmann-La Roche Inc. | Oxime glucokinase activators |
EP2117577A1 (fr) | 2007-01-05 | 2009-11-18 | Arena Pharmaceuticals, Inc. | Récepteur couplé aux protéines g et modulateur dudit récepteur pour le traitement de troubles neurologiques liés au gaba et notamment de troubles liés au sommeil |
JP5478488B2 (ja) | 2007-06-20 | 2014-04-23 | メルク・シャープ・アンド・ドーム・コーポレーション | Janusキナーゼの阻害剤 |
EP2195304B1 (fr) * | 2007-10-08 | 2014-01-08 | Advinus Therapeutics Private Limited | Dérivés acétamide comme activateurs de la glucokinase, leur procédé et applications médicinales |
EP2212293A4 (fr) | 2007-10-24 | 2010-12-01 | Merck Sharp & Dohme | Antagonistes des canaux calciques de type t à base d'amide hétérocyclique |
CA2703471A1 (fr) | 2007-10-24 | 2009-04-30 | Merck Sharp & Dohme Corp. | Antagonistes des canaux calciques de type t a base d'amide de pyrazinyle |
BRPI0818244A2 (pt) | 2007-10-24 | 2015-06-16 | Merck Sharp & Dohme | Composto, composição farmacêutica, uso de um composto, e, método para tratamento de um distúrbio ou doença |
WO2009118596A2 (fr) * | 2008-03-26 | 2009-10-01 | Glenmark Pharmaceuticals, S. A. | Dérivés de phtalimide en tant que modulateurs de trpa1 |
US20100305120A1 (en) | 2008-04-04 | 2010-12-02 | Biomarin Iga Limited | Compounds for treating muscular dystrophy |
WO2010004390A1 (fr) * | 2008-06-17 | 2010-01-14 | Glenmark Pharmaceuticals, S.A. | Dérivés de quinazoline dione en tant que modulateurs de trpa1 |
KR101052065B1 (ko) * | 2008-10-15 | 2011-07-27 | 한국과학기술연구원 | 칼슘이온 채널 조절제로서 유효한 피라졸릴메틸아민-피페라진 유도체와 이의 제조방법 |
WO2010073011A2 (fr) | 2008-12-23 | 2010-07-01 | Betagenon Ab | Composés utiles comme médicaments |
US8541424B2 (en) | 2008-12-23 | 2013-09-24 | Abbott Laboratories | Anti-viral compounds |
EP2393811A1 (fr) | 2009-02-04 | 2011-12-14 | Pfizer Inc. | Dérivés de 4-amino-7,8-dihydropyrido[4,3-d]pyrimidin-5(6h)-one |
US8399436B2 (en) * | 2009-04-24 | 2013-03-19 | Glaxo Group Limited | N-pyrazolyl carboxamides as CRAC channel inhibitors |
JP2012524754A (ja) * | 2009-04-24 | 2012-10-18 | グラクソ グループ リミテッド | Cracチャネル阻害剤としてのピラゾールおよびトリアゾ−ルカルボキサミド |
AU2010255727B2 (en) | 2009-06-04 | 2013-02-28 | Novartis Ag | 1H-imidazo[4,5-c]quinolinone derivatives |
WO2011022315A1 (fr) | 2009-08-19 | 2011-02-24 | Merck Sharp & Dohme Corp. | Antagonistes de canal calcium de type t de pyrazinylphénylamide |
US8377970B2 (en) * | 2009-10-08 | 2013-02-19 | Rhizen Pharmaceuticals Sa | Modulators of calcium release-activated calcium channel |
US8993612B2 (en) * | 2009-10-08 | 2015-03-31 | Rhizen Pharmaceuticals Sa | Modulators of calcium release-activated calcium channel and methods for treatment of non-small cell lung cancer |
WO2011053542A1 (fr) | 2009-10-30 | 2011-05-05 | Merck Sharp & Dohme Corp. | Antagonistes des canaux calciques de type t amides hétérocycliques |
WO2011084402A1 (fr) | 2009-12-21 | 2011-07-14 | Merck Sharp & Dohme Corp. | Inhibiteurs de tyrosine kinase |
WO2011093352A1 (fr) | 2010-01-27 | 2011-08-04 | 武田薬品工業株式会社 | Dérivé de thiazole |
EP2402327B1 (fr) | 2010-06-29 | 2018-03-07 | Impetis Biosciences Ltd. | Composés d'acétamide en tant qu'activateurs de la glucokinase, leur procédé et applications médicales |
EP2609092B1 (fr) | 2010-08-26 | 2015-04-01 | Boehringer Ingelheim International GmbH | Composés oxadiazole, inhibiteurs de la production de leucotriènes |
KR20120063283A (ko) | 2010-12-07 | 2012-06-15 | 제일약품주식회사 | 신규한 피라졸로 피리딘 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 포함하는 약학적 조성물 |
SG192766A1 (en) | 2011-03-07 | 2013-09-30 | Pfizer | Fluoro-pyridinone derivatives useful as antibacterial agents |
US8759380B2 (en) | 2011-04-22 | 2014-06-24 | Cytokinetics, Inc. | Certain heterocycles, compositions thereof, and methods for their use |
UY34200A (es) | 2011-07-21 | 2013-02-28 | Bayer Ip Gmbh | 3-(fluorovinil)pirazoles y su uso |
US9006235B2 (en) | 2012-03-06 | 2015-04-14 | Bristol-Myers Squibb Company | Inhibitors of human immunodeficiency virus replication |
EP2991994B1 (fr) * | 2013-05-01 | 2018-08-15 | Vitae Pharmaceuticals, Inc. | Inhibiteurs du ror-gamma à base de thiazolopyrrolidine |
AR096393A1 (es) | 2013-05-23 | 2015-12-30 | Bayer Cropscience Ag | Compuestos heterocíclicos pesticidas |
EP2848615A1 (fr) * | 2013-07-03 | 2015-03-18 | Almirall, S.A. | Nouveaux dérivés de pyrazole utilisés comme modulateurs du canal CRAC |
KR101685993B1 (ko) | 2014-05-15 | 2016-12-13 | 한국과학기술연구원 | 전압개폐 칼슘이온채널 억제 활성화능을 갖는 n-(피라졸릴메틸)아릴설폰아마이드 화합물 및 이를 포함하는 약학적 조성물 |
HUE040489T2 (hu) | 2014-06-03 | 2019-03-28 | Idorsia Pharmaceuticals Ltd | Pirazolvegyületek és alkalmazásuk t-típusú kalciumcsatorna-blokkolókként |
US10246426B2 (en) | 2014-09-15 | 2019-04-02 | Idorsia Pharmaceuticals Ltd | Triazole compounds as T-type calcium channel blockers |
CN107406420B (zh) | 2015-01-30 | 2020-11-06 | 纽罗克里生物科学有限公司 | 取代的三唑及与其相关的方法 |
WO2016138472A1 (fr) * | 2015-02-27 | 2016-09-01 | Calcimedica, Inc. | Traitement de la pancréatite |
-
2015
- 2015-06-02 HU HUE15728640A patent/HUE040489T2/hu unknown
- 2015-06-02 PE PE2016002493A patent/PE20170129A1/es unknown
- 2015-06-02 ES ES15728640T patent/ES2696351T3/es active Active
- 2015-06-02 RS RS20181305A patent/RS57943B1/sr unknown
- 2015-06-02 UA UAA201613231A patent/UA121548C2/uk unknown
- 2015-06-02 TN TN2016000542A patent/TN2016000542A1/en unknown
- 2015-06-02 MX MX2016015923A patent/MX2016015923A/es active IP Right Grant
- 2015-06-02 NZ NZ727818A patent/NZ727818A/en unknown
- 2015-06-02 AU AU2015270118A patent/AU2015270118C1/en active Active
- 2015-06-02 LT LTEP15728640.2T patent/LT3152199T/lt unknown
- 2015-06-02 JP JP2016571138A patent/JP6195684B2/ja active Active
- 2015-06-02 KR KR1020167036470A patent/KR101906031B1/ko active IP Right Grant
- 2015-06-02 US US15/316,100 patent/US9932314B2/en active Active
- 2015-06-02 TR TR2018/16624T patent/TR201816624T4/tr unknown
- 2015-06-02 DK DK15728640.2T patent/DK3152199T3/en active
- 2015-06-02 SI SI201530461T patent/SI3152199T1/sl unknown
- 2015-06-02 TW TW108115051A patent/TWI690513B/zh active
- 2015-06-02 EA EA201692521A patent/EA031104B1/ru not_active IP Right Cessation
- 2015-06-02 PL PL15728640T patent/PL3152199T3/pl unknown
- 2015-06-02 PT PT15728640T patent/PT3152199T/pt unknown
- 2015-06-02 SG SG11201609974PA patent/SG11201609974PA/en unknown
- 2015-06-02 EP EP15728640.2A patent/EP3152199B1/fr active Active
- 2015-06-02 AR ARP150101743A patent/AR100712A1/es active IP Right Grant
- 2015-06-02 CA CA2947002A patent/CA2947002C/fr active Active
- 2015-06-02 WO PCT/IB2015/054164 patent/WO2015186056A1/fr active Application Filing
- 2015-06-02 CN CN201580028246.2A patent/CN106414429B/zh active Active
- 2015-06-02 TW TW104117850A patent/TWI675827B/zh active
- 2015-06-02 MA MA40281A patent/MA40281B1/fr unknown
-
2016
- 2016-11-09 PH PH12016502230A patent/PH12016502230A1/en unknown
- 2016-11-29 IL IL249275A patent/IL249275B/en active IP Right Grant
- 2016-12-01 CL CL2016003092A patent/CL2016003092A1/es unknown
- 2016-12-21 ZA ZA2016/08821A patent/ZA201608821B/en unknown
-
2017
- 2017-12-19 US US15/847,611 patent/US10065929B2/en active Active
-
2018
- 2018-10-12 HR HRP20181670TT patent/HRP20181670T1/hr unknown
- 2018-11-15 CY CY181101214T patent/CY1120864T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA40281B1 (fr) | Composés de pyrazole et leur utilisation en tant qu' agents de blocage des canaux calciques de type t | |
CL2017001426A1 (es) | Nuevos compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidin-2,7-diona 3-sustituidos para el tratamiento y profilaxis de infecciones virales. | |
ZA201701299B (en) | Glycosidase inhibitors | |
MX2022005160A (es) | Oxisteroles y metodos de uso de los mismos. | |
MX2022012313A (es) | Oxisteroles y metodos de uso de los mismos. | |
CO2018000589A2 (es) | Oxiesteroles y composiciones farmacéuticas que los contienen | |
MA42109A (fr) | Amides hétérocycliques utilisés en tant qu'inhibiteurs de kinase | |
ECSP16005566A (es) | Sulfonamidas como moduladores de canales de sodio | |
PE20151781A1 (es) | Piridonamidas como moduladores de canales de sodio | |
BR112017006251A2 (pt) | novos compostos | |
GT201500334A (es) | Compuestos de 3,4- dihidroisoquinolin-2-(1h)-ilo | |
AR094918A1 (es) | Compuestos de tetrahidropirrolotiazina como inhibidores de bace | |
MA44820A1 (fr) | Amides hétérocycliques a utiliser en tant qu'inhibiteurs de kinase | |
MA39956A (fr) | Analogues du benzomorphane et leur utilisation | |
MA40302B1 (fr) | Dérivés de carbazole | |
MA39152B1 (fr) | Cyclopentanes substitués en 1,2 utilisés comme antagonistes du récepteur d'orexine | |
SA518390920B1 (ar) | مركبات فينوكسي أسيتاميد معالجة بإضافة حلقة | |
MX2018002006A (es) | Benzamidas apareadas novedosas. | |
MA39315A1 (fr) | Dérivés de pyridazine à utiliser dans la prévention ou le traitement d'un trouble ataxique | |
MA40366A (fr) | Dérivés de tétrahydroquinoline à titre d'inhibiteurs des bromodomaines | |
CL2017002498A1 (es) | Piridopirimidinonas y su uso como modulares del receptor nmda | |
CL2015002188A1 (es) | Agentes analgésicos oculares tópicos | |
MA38326A1 (fr) | Amides hétérocycliques à utiliser en tant qu'inhibiteurs de kinase | |
FR3022245B1 (fr) | Derives de 3,5-dihydro-2h-pyrazolo[4,3-c]pyridin-3-one et leur utilisation | |
MA39071A1 (fr) | Benzamides substitués et leurs méthodes d'utilisation |